Cell Therapeutics (CTIC) to Get EMA Opinion on Pixuvri MAA in Mid-February FY12
Tweet
Share
E-mailGet Alerts CTIC Hot Sheet
Join SI Premium – FREE
Cell Therapeutics, Inc. (Nasdaq: CTIC) reports that, following discussions with the European Medicines Agency's Committee for Medicinal Products for Human Use, the CHMP may issue an opinion on CTI's Marketing Authorization Application for Pixuvri in mid-February.
In the interim, CTI will continue to work with the CHMP on the Summary of Product Characteristics and other labeling items for Pixuvri. CTI is seeking an authorization to market Pixuvri in the E.U. for the treatment of adult patients with multiple relapsed or refractory aggressive non-Hodgkin's B cell lymphomas.
If approved by the EMA, Pixuvri would address an unmet medical need, as there are no approved therapies for these patients.
In the U.S., the Food and Drug Administration has set a Prescription Drug User Fee Act goal date of April 24, 2012 for a decision on the New Drug Application for Pixuvri in the same indication.
In the interim, CTI will continue to work with the CHMP on the Summary of Product Characteristics and other labeling items for Pixuvri. CTI is seeking an authorization to market Pixuvri in the E.U. for the treatment of adult patients with multiple relapsed or refractory aggressive non-Hodgkin's B cell lymphomas.
If approved by the EMA, Pixuvri would address an unmet medical need, as there are no approved therapies for these patients.
In the U.S., the Food and Drug Administration has set a Prescription Drug User Fee Act goal date of April 24, 2012 for a decision on the New Drug Application for Pixuvri in the same indication.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- loanDepot receives NYSE non-compliance notice over stock price
- Gray Media closes $750M note offering to refinance higher-rate debt
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
